Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma

被引:24
作者
De Panfilis, Giuseppe [1 ]
Campanini, Nicoletta [2 ]
Santini, Marcello [1 ]
Mori, Giovanni [3 ]
Tognetti, Elena [1 ]
Maestri, Roberta [2 ]
Lombardi, Mara [1 ]
Froio, Elisabetta [2 ]
Ferrari, Donata [1 ]
Ricci, Roberto [2 ]
机构
[1] Univ Parma, Dermatol Clin, Dermatol Sect, Dept Surg Sci, I-43100 Parma, Italy
[2] Univ Parma, Dept Pathol & Lab Med, I-43100 Parma, Italy
[3] Univ Parma, Dept Gen & Inorgan Chem Analyt Chem & Phys Chem, I-43100 Parma, Italy
关键词
D O I
10.1038/sj.jid.5701046
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Although tumor-infiltrating lymphocytes (TILs) of primary cutaneous melanoma WCM) include cytolytic T cells able to exert anti-PCM immunity, progression of PCM most frequently occurs, raising the hypothesis that the PCM microenvironment may also exert suppressive forces, for example, possibly developed by regulatory T (TREG) lymphocytes. The aim of this study was to investigate whether TILs of PCMs include lymphocytes bearing the transcription factor forkhead box protein P3 (FOXP3), which is the T-REG lineage specification molecule in mice, and is debated to have a similar role in humans. Fourteen patients with PCM were selected, of which four had radial growth phase (RGP) stage I melanoma, five had vertical growth phase (VGP) stage I melanoma, and five had VGP stage III-IV melanoma. Formalin-fixed, paraffin-embedded sections were utilized for immunohistochemical single and double stainings. TILs of PCMs included FOXP3-bearing lymphocytes, which predominantly were CD20- and CD8-negative, but CD3-, CD4-, and CD25-positive, thus consistent with the standard immunophenotypical characteristics of "natural" T-REG cells. Further, the proportions of FOXP3-bearing lymphocytes were higher in vertical than in RGP (P-0.001), as well as in late than in early melanoma stages (P<0.001). Should these FOXP3-bearing lymphocytes actually exert regulatory capabilities within the PCM microenvironment, they may suppress "in vivo" the local anti-PCM immune response, thus favoring melanoma progression.
引用
收藏
页码:676 / 684
页数:9
相关论文
共 75 条
[1]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[2]   Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation [J].
Asano, M ;
Toda, M ;
Sakaguchi, N ;
Sakaguchi, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :387-396
[3]   An evidence-based staging system for cutaneous melanoma [J].
Balch, CM ;
Soong, SJ ;
Atkins, MB ;
Buzaid, AC ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (03) :131-149
[4]   Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells [J].
Banham, Alison H. .
TRENDS IN IMMUNOLOGY, 2006, 27 (12) :541-544
[5]   Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma [J].
Cesana, GC ;
DeRaffele, G ;
Cohen, S ;
Moroziewicz, D ;
Mitcham, J ;
Stoutenburg, J ;
Cheung, K ;
Hesdorffer, C ;
Kim-Schulze, S ;
Kaufman, HL .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1169-1177
[6]   Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma [J].
Chakraborty, NG ;
Chattopadhyay, S ;
Mehrotra, S ;
Chhabra, A ;
Mukherji, B .
HUMAN IMMUNOLOGY, 2004, 65 (08) :794-802
[7]   MODEL PREDICTING SURVIVAL IN STAGE-I MELANOMA BASED ON TUMOR PROGRESSION [J].
CLARK, WH ;
ELDER, DE ;
GUERRY, D ;
BRAITMAN, LE ;
TROCK, BJ ;
SCHULTZ, D ;
SYNNESTVEDT, M ;
HALPERN, AC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1893-1904
[8]   CD4+ CD25+ FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer [J].
Clarke, Sarah L. ;
Betts, Gareth J. ;
Plant, Andrea ;
Wright, Kate L. ;
El-Shanawany, Tariq M. ;
Harrop, Richard ;
Torkington, Jared ;
Rees, Brian I. ;
Williams, Geraint T. ;
Gallimore, Awen M. ;
Godkin, Andrew J. .
PLOS ONE, 2006, 1 (02)
[9]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO
[10]  
2-5